Ontology highlight
ABSTRACT: Objective
The aim of this study was to investigate long-term clinical outcomes of extended treatment with CT-P10, a rituximab biosimilar, compared with rituximab reference products sourced from the USA and the EU (US-RTX and EU-RTX) in rheumatoid arthritis (RA) for up to 48 weeks.Methods
In this multinational, randomized, double-blind trial, adults with active RA received up to two courses of CT-P10, US-RTX, or EU-RTX alongside methotrexate. Efficacy endpoints included Disease Activity Score 28-joint count (DAS28) and American College of Rheumatology (ACR) response rates. Pharmacokinetics, pharmacodynamics, immunogenicity, and safety were also assessed.Results
Of 372 patients randomized to the study drug, 330 (88.7%) completed the second treatment course. Mean chang
SUBMITTER: Suh CH
PROVIDER: S-EPMC6373391 | biostudies-literature | 2019 Feb
REPOSITORIES: biostudies-literature